Inactivated influenza vaccines: Recent progress and implications for the elderly

Drugs and Aging

Volumn 28, Issue 2, 2011, Pages 93-106

  Parodi, Valentina ^a   De Florentiis, Daniela ^a   Martini, Mariano ^a   Ansaldi, Filippo ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Elderly; Influenza virus infections, prevention; Influenza virus vaccine, therapeutic use

Indexed keywords

ADIUGRIP; ADJUVANT; ALUMINUM; ALUMINUM POTASSIUM SULFATE; ANTHRAX VACCINE; ANTIGEN; AS 03; BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; ISCOM; ISIFLU V; LIPOSOME; LYME DISEASE VACCINE; MEASLES VACCINE; MIFAMURTIDE; MUMPS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VIROSOME; WATER OIL CREAM; YELLOW FEVER VACCINE;

AGED; ANTHRAX; ANTIBODY TITER; CLINICAL TRIAL (TOPIC); DIPHTHERIA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HAEMOPHILUS INFECTION; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INJECTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LOW DRUG DOSE; LYME DISEASE; MEASLES; MICROINJECTION; MORTALITY; MUMPS; OBSERVATIONAL STUDY; PANDEMIC INFLUENZA; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROTAVIRUS INFECTION; RUBELLA; TETANUS; TREATMENT OUTCOME; TUBERCULOSIS; TYPHOID FEVER; VIRUS LIKE AGENT; VIRUS STRAIN; YELLOW FEVER;

ADJUVANTS, IMMUNOLOGIC; AGED; AGING; CLINICAL TRIALS AS TOPIC; EFFICIENCY; HUMANS; IMMUNITY; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, INACTIVATED;

EID: 79551551834     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11586770-000000000-00000     Document Type: Review

References (105)

1. Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis 2010; 50 (5): 747-51
2. Zambon MC, Stockton JD, Clewley JP, et al. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 2001; 358 (9291): 1410-6
3. Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009; 27 (37): 5043-53
4. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289 (2): 179-86
5. Lemaitre M, Carrat F. Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC Infect Dis 2010; 10: 162
6. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002; 2 (11): 659-66
7. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348 (14): 1322-32
8. Fleming DM, Cross KW, Pannell RS. Influenza and its relationship to circulatory disorders. Epidemiol Infect 2005; 133 (2): 255-62
9. Fiore AE, Shay DK, Broder K, et al. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57 (RR-7): 1-60
10. Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002; 35 (4): 370-7
11. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24 (8): 1159-69
12. Weinberger B, Herndler-Brandstetter D, Schwanninger A, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46 (7): 1078-84
13. Renshaw M, Rockwell J, Engleman C, et al. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 2002; 169 (9): 4697-701
14. Aspinall R, Del Giudice G, Effros RB, et al. Challenges for vaccination in the elderly. Immun Ageing 2007; 4: 9-12
15. Ritter MA, Palmer DB. The human thymic microenvironment: new approaches to functional analysis. Semin Immunol 1999; 11 (1): 13-21
16. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396 (6712): 690-5
17. Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol 2005; 26 (7): 360-6
18. de Jong JC, Beyer WE, Palache AM, et al. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61 (1): 94-9
19. de Jong JC, Palace AM, BeyeWE, et al. Haemagglutinationinhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115: 63-73
20. Del Giudice G, Hilbert AK, Bugarini R, et al. An MF59- adjuvanted inactivated influenza vaccine containing A/ Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/ Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24 (16): 3063-5
21. Kojimahara N, Maeda A, Kase T, et al. Cross-reactivity of influenza A(H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 2006; 24 (33-34): 5966-9
22. Ansaldi F, Bacilieri S, Durando P, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26 (12): 1525-9
23. Ansaldi F, Canepa P, Parodi V, et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009; 27 (25-26): 3345-8
24. Ansaldi F, ZancolliM, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010; 28 (25): 4123-9
25. Glenny AT, Pope CG, Waddington H, et al. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926; 29: 31-40
26. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 2003; 8 (20): 934-43
27. Dupuis M, Murphy TJ, Higgins D, et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998; 186 (1): 18-27
28. Reed SG, Bertholet S, Coler RN, et al. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30 (1): 23-32
29. Mosca F, Tritto E, Muzzi A, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008; 105 (30): 10501-6
30. Schultze V, D'Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine 2008; 26 (26): 3209-22
31. Harandi AM, Medaglini D, Shattock RJ, et al. Vaccine adjuvants: a priority for vaccine research. Vaccine 2010; 28 (12): 2363-6
32. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009; 27 (25-26): 3331-4
33. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367 (9523): 1657-64
34. Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenzaH5N1 vaccine in adults. J Infect Dis 2008; 197 (5): 667-75
35. Brady RC, Treanor JJ, Atmar RL, et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009; 27 (37): 5091-5
36. Keitel WA, Campbell JD, Treanor JJ, et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008; 198 (9): 1309-16
37. Vajo Z, Tamas F, Sinka L, et al. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010; 375 (9708): 49-55
38. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: amulticentre, double-blind, randomised, placebocontrolled trial. Lancet 2010; 375 (9708): 56-66
39. Cvjetanovic B, Uemura K. The present status of field and laboratory studies of typhoid and paratyphoid vaccines. Bull WHO 1965; 32: 29-36
40. Bomford R. Aluminium salts: perspective in their use as adjuvants. In: Gregoriadis G, Allison AC, Poste G, editors. Immunological adjuvants and vaccines. New York: Plenum Publishing Corp., 1989: 35-71 41.
41. Lindblad EB. Aluminium adjuvant-in retrospect and prospect. Vaccine 2004; 22: 3658-68
42. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19 (17-19): 2673-80
43. Bloch KE. Sterol structure and membrane function. CRC Crit Rev Biochem 1983; 14 (1): 47-92
44. Del Giudice G, Fragapane E, Bugarini R, et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 2006; 13 (9): 1010-3
45. Khurana S, Chearwae W, Castellino F, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2 (15): 15ra5
46. Huckriede A, Bungener L, Veer W, et al. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine 2003; 21 (9-10): 925-31
47. Bungener L, Huckriede A, de Mare A, et al. Virosomemediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 2005; 23 (10): 1232-41
48. Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine 2003; 21 (9-10): 921-4
49. Evison J, Farese S, Seitz M, et al. Randomized, doubleblind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009; 48 (10): 1402-12
50. Herzog C, Hartmann K, Künzi V, et al. Eleven years of Inflexal V: a virosomal adjuvanted influenza vaccine. Vaccine 2009; 27: 4381-7
51. de Bruijn IA, Nauta J, Gerez L, et al. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad) in elderly subjects. Vaccine 2006; 24 (44-46): 6629-31
52. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin Infect Dis 2010; 50 (10): 1331-8
53. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351 (22): 2286-94
54. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6 (5): 699-710
55. Squarcione S, Sgricia S, Biasio LR, et al. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003; 21 (11-12): 1268-74
56. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49 (3): 177-84
57. Li R, Fang H, Li Y, et al. Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects. Immun Ageing 2008; 5: 2
58. Baldo V, Baldovin T, Floreani A, et al. Response to influenza vaccine in people with non-protective HI antibody titers. Eur J Epidemiol 2006; 21 (11): 843-5
59. Baldo V, Baldovin T, Floreani A, et al., Family Medicine Group. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007; 27 (5): 542-7
60. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21 (15): 1687-93
61. Stephenson I, Nicholson KG, Glück R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362 (9400): 1959-66
62. Stephenson I, Bugarini R, Nicholson KG, et al. Crossreactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59- adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J InfectDis 2005; 191 (8): 1210-5
63. European Medicines Agency (EMA). Focetria, pandemic influenza vaccine (surface antigen, inactivated, adjuvanted) A/California/7/2009 (H1N1) [online]. Available from URL: http://www.emea.europa.eu/influenza/vaccines/ focetria/focetria-pi.html [Accessed 2010 Feb 10]
64. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361 (25): 2424-35
65. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370 (9587): 580-9
66. Baras B, Bouveret N, Devaster JM, et al. A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respi Viruses 2008; 2 (6): 251-60
67. Chu DW, Hwang SJ, Lim FS, et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27 (52): 7428-35
68. Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28 (7): 1740-5
69. Leroux-Roels I, Roman F, Forgus S, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28 (3): 849-57
70. Leroux-Roels I, Clement F, Leroux-Roels G, et al. Adjuvanted influenza vaccines improve anti-influenza cellular mediated immunity impaired in elderly [poster]. Influenza Vaccines for the World; 2006 Oct 18-20; Vienna
71. Leroux-Roels I, Oostvogels L, Hons E, et al. Reactogenicity and safety of adjuvanted influenza vaccines administered in elderly [abstract plus poster]. Influenza Vaccines for the World; 2006 Oct 18-20; Vienna
72. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340: c2649
73. Carmona A, Omeñaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010; 28 (36): 5837-44
74. Cryz SJ, Que JU, Glück R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 1996; 14 (14): 1381-3
75. Felnerova D, Viret JF, Glück R, et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004; 15 (6): 518-29
76. Daemen T, de Mare A, Bungener L, et al. Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 2005; 57 (3): 451-63
77. Glück R, Wegmann A. Influenza vaccination in the elderly. Dev Comp Immunol 1997; 21 (6): 501-7
78. Loutan L, Bovier P, Althaus B, et al. Inactivated virosome hepatitis A vaccine. Lancet 1994; 343 (8893): 322-4
79. Glück R,Metcalfe IC. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems. Vaccine 2003; 21 (7-8): 611-5
80. de Bruijn IA, Nauta J, Gerez L, et al. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 2004; 103 (1-2): 139-45
81. de Bruijn I, Meyer I, Gerez L, et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007; 26 (1): 119-27
82. de Bruijn IA, Nauta J, Cramer WC, et al. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2005; 23 Suppl. 1: S39-49
83. Huckriede A, Bungener L, Stegmann T, et al. The virosome concept for influenza vaccines. Vaccine 2005; 23 Suppl. 1: S26-38
84. Kanra G, Marchisio P, Feiterna-Sperling C, et al. Comparison of immunogenicity and tolerability of a virosomeadjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004; 23: 300-6
85. Baldo V,Menegon T, Bonello C, et al. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001; 19 (25-26): 3472-5
86. Pregliasco F, Mensi C, Serpilli W, et al. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging 2001; 13 (1): 38-43
87. Ruf BR, Colberg K, Frick M, et al. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004; 32 (4): 191-8
88. Baldo V, Baldovin T, Pellegrini M, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010; 2010: 517198
89. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008; 26 (26): 3197-208
90. World Health Organization. WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies [WHO/EMC/ ZOO/96.6]. Geneva: World Health Organization [online]. Available from URL: http://www.who.int/rabies/en/WHO- recommendation-post-exp-treatment.pdf [Accessed 2010 Nov 29]
91. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198 (5): 650-8
92. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7 (8): 1201-14
93. Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009; 27 (52): 7304-12
94. Van Damme P, Arnou R, Kafeja F, et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010; 10: 134
95. Arnou R, Eavis P, Pardo JR, et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years. Human vaccines 2010; 6: 346-54
96. Mostow SR, Schoenbaum SC, Dowdle WR, et al. Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation. Postgrad Med J 1973; 49: 152-8
97. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166: 1121-7
98. Ruben FL, Jackson GG. A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis 1972; 125: 656-64
99. Palache AM, Beyer WE, Sprenger MJ, et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 1993; 11: 3-9
100. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25: 7656-63
101. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367: 1657-64
102. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354: 1343-51
103. Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375 (9708): 41-8
104. Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated influenza vaccine for persons aged > or = 65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59 (16): 485-6
105. Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200: 172-80